- Home
- CRON vs ZYME Comparison
CRON vs ZYME Comparison
Compare CRON & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- ZYME
- Stock Information
- Founded
- CRON N/A
- ZYME 2003
- Country
- CRON Canada
- ZYME United States
- Employees
- CRON N/A
- ZYME N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- ZYME Health Care
- Exchange
- CRON Nasdaq
- ZYME Nasdaq
- Market Cap
- CRON 736.2M
- ZYME 867.6M
- IPO Year
- CRON N/A
- ZYME 2017
- Fundamental
- Price
- CRON $2.05
- ZYME $13.33
- Analyst Decision
- CRON
- ZYME Buy
- Analyst Count
- CRON 0
- ZYME 7
- Target Price
- CRON N/A
- ZYME $19.50
- AVG Volume (30 Days)
- CRON 1.4M
- ZYME 499.2K
- Earning Date
- CRON 08-07-2025
- ZYME 08-07-2025
- Dividend Yield
- CRON N/A
- ZYME N/A
- EPS Growth
- CRON N/A
- ZYME N/A
- EPS
- CRON 0.13
- ZYME N/A
- Revenue
- CRON $124,589,000.00
- ZYME $93,384,000.00
- Revenue This Year
- CRON $25.49
- ZYME $44.71
- Revenue Next Year
- CRON $7.45
- ZYME $34.57
- P/E Ratio
- CRON $15.93
- ZYME N/A
- Revenue Growth
- CRON 33.92
- ZYME 85.05
- 52 Week Low
- CRON $1.60
- ZYME $9.03
- 52 Week High
- CRON $2.50
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- CRON 53.10
- ZYME 49.83
- Support Level
- CRON $1.99
- ZYME $13.98
- Resistance Level
- CRON $2.15
- ZYME $15.00
- Average True Range (ATR)
- CRON 0.06
- ZYME 0.59
- MACD
- CRON 0.00
- ZYME -0.01
- Stochastic Oscillator
- CRON 35.14
- ZYME 25.11
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.